Compare Stocks: ALLR, CRDF, BRTX, and OKYO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.22 -2.4%	$1.30	$0.77 ▼ $1.88	$19.41M	0.56	78,073 shs	200,009 shs
BRTX Biorestorative Therapies	$2.67 -3.3%	$4.84	$2.61 ▼ $34.60	$3.69M	0.83	24,393 shs	10,281 shs
CRDF Cardiff Oncology	$1.21	$1.01	$0.76 ▼ $3.31	$94.13M	1.46	608,765 shs	493,259 shs
OKYO OKYO Pharma	$1.40 -2.1%	$1.55	$1.34 ▼ $3.20	$73.47M	0.03	71,907 shs	53,743 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	-14.08%	-10.29%	-14.69%	-32.60%
BRTX Biorestorative Therapies	0.00%	-9.80%	-39.37%	-62.13%	-91.50%
CRDF Cardiff Oncology	0.00%	+11.01%	+22.97%	-21.43%	-40.69%
OKYO OKYO Pharma	0.00%	-10.83%	-7.28%	-7.89%	-35.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.22 -2.4%	$1.30	$0.77 ▼ $1.88	$19.41M	0.56	78,073 shs	200,009 shs
BRTX Biorestorative Therapies	$2.67 -3.3%	$4.84	$2.61 ▼ $34.60	$3.69M	0.83	24,393 shs	10,281 shs
CRDF Cardiff Oncology	$1.21	$1.01	$0.76 ▼ $3.31	$94.13M	1.46	608,765 shs	493,259 shs
OKYO OKYO Pharma	$1.40 -2.1%	$1.55	$1.34 ▼ $3.20	$73.47M	0.03	71,907 shs	53,743 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	-14.08%	-10.29%	-14.69%	-32.60%
BRTX Biorestorative Therapies	0.00%	-9.80%	-39.37%	-62.13%	-91.50%
CRDF Cardiff Oncology	0.00%	+11.01%	+22.97%	-21.43%	-40.69%
OKYO OKYO Pharma	0.00%	-10.83%	-7.28%	-7.89%	-35.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	2.00	Hold	$10.25	740.16% Upside
BRTX Biorestorative Therapies	1.00	Sell	N/A	N/A
CRDF Cardiff Oncology	2.14	Hold	$7.50	519.83% Upside
OKYO OKYO Pharma	2.40	Hold	$5.67	304.76% Upside

Current Analyst Ratings Breakdown

Latest ALLR, CRDF, BRTX, and OKYO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	BRTX Biorestorative Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/19/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	OKYO OKYO Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $5.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	$320K	60.66	N/A	N/A	$0.61 per share	2.00
BRTX Biorestorative Therapies	$360K	10.24	N/A	N/A	$0.77 per share	3.47
CRDF Cardiff Oncology	$590K	159.54	N/A	N/A	$0.67 per share	1.81
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	11/13/2026 (Estimated)
BRTX Biorestorative Therapies	-$14.24M	-$1.07	N/A	N/A	N/A	-3,088.27%	-508.42%	-230.94%	9/15/2026 (Estimated)
CRDF Cardiff Oncology	-$45.85M	-$0.60	N/A	N/A	N/A	-7,885.43%	-103.10%	-75.52%	11/5/2026 (Estimated)
OKYO OKYO Pharma	-$8.95M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)

Latest ALLR, CRDF, BRTX, and OKYO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/15/2026	Q2 2026	BRTX Biorestorative Therapies	-$2.00	N/A	N/A	N/A	$0.60 million	N/A
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/11/2026	Q2 2026	CRDF Cardiff Oncology	-$0.1196	-$0.14	-$0.0204	-$0.14	$0.06 million	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
BRTX Biorestorative Therapies	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	1.11	1.11
BRTX Biorestorative Therapies	N/A	2.35	2.35
CRDF Cardiff Oncology	N/A	3.30	3.30
OKYO OKYO Pharma	N/A	2.43	2.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
BRTX Biorestorative Therapies	69.38%
CRDF Cardiff Oncology	16.29%
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.16%
BRTX Biorestorative Therapies	13.60%
CRDF Cardiff Oncology	8.80%
OKYO OKYO Pharma	40.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.91 million	15.89 million	Not Optionable
BRTX Biorestorative Therapies	7	1.38 million	1.19 million	Not Optionable
CRDF Cardiff Oncology	20	77.79 million	70.95 million	Optionable
OKYO OKYO Pharma	7	52.48 million	31.25 million	Not Optionable

ALLR, CRDF, BRTX, and OKYO Headlines

Recent News About These Companies

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

September 9, 2026 | globenewswire.com

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

September 8, 2026 | globenewswire.com

Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Declines By 38.4%

August 31, 2026 | marketbeat.com

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

July 28, 2026 | globenewswire.com

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

July 27, 2026 | globenewswire.com

OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain

July 25, 2026 | ophthalmologytimes.comO

OKYO Pharma Announces Purchase of Shares by Director

July 23, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

July 23, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chairman

July 22, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

July 22, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

July 22, 2026 | globenewswire.com

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

July 21, 2026 | markets.businessinsider.com

OKYO Pharma Announces Purchase of Shares by Chairman

July 21, 2026 | globenewswire.com

Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources

July 20, 2026 | proactiveinvestors.com

OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans

July 20, 2026 | proactiveinvestors.com

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

July 20, 2026 | globenewswire.com

OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium

July 14, 2026 | theglobeandmail.com

OKYO Pharma announces positive feedback from US FDA Type D Meeting and accelerates urcosimod into global phase 3 trial for NCP

July 11, 2026 | pharmabiz.comP

OKYO Pharma advances toward Phase 3 FDA trial - ICYMI

July 11, 2026 | proactiveinvestors.com

Phase 3 trial to study urcosimod in neuropathic corneal pain

July 10, 2026 | healio.comH

Okyo Pharma

July 10, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, CRDF, BRTX, and OKYO Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.22 -0.03 (-2.40%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.19 -0.03 (-2.46%)

As of 09/11/2026 07:58 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Biorestorative Therapies NASDAQ:BRTX

$2.67 -0.09 (-3.26%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.71 +0.04 (+1.50%)

As of 09/11/2026 06:46 PM Eastern

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Cardiff Oncology NASDAQ:CRDF

$1.21 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.21 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

OKYO Pharma NASDAQ:OKYO

$1.40 -0.03 (-2.10%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.40 0.00 (-0.36%)

As of 09/11/2026 07:30 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, CRDF, BRTX, and OKYO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, CRDF, BRTX, and OKYO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, CRDF, BRTX, and OKYO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, CRDF, BRTX, and OKYO Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Biorestorative Therapies NASDAQ:BRTX

Cardiff Oncology NASDAQ:CRDF

OKYO Pharma NASDAQ:OKYO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, CRDF, BRTX, and OKYO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, CRDF, BRTX, and OKYO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, CRDF, BRTX, and OKYO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, CRDF, BRTX, and OKYO Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Biorestorative Therapies NASDAQ:BRTX

Cardiff Oncology NASDAQ:CRDF

OKYO Pharma NASDAQ:OKYO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools